Clinical Trials Logo

Dermatitis clinical trials

View clinical trials related to Dermatitis.

Filter by:

NCT ID: NCT02067234 Withdrawn - Atopic Dermatitis Clinical Trials

A Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families

Start date: January 2015
Phase: N/A
Study type: Interventional

The goal of the current investigation is to determine whether the inclusion of a parent/patient psychoeducational session in initial dermatology appointments with new pediatric atopic dermatitis patients affects (a) extent of medical follow-up, (b) patient's quality of life, and (c) parenting stress in comparison to treatment as usual for initial pediatric dermatology appointments for new pediatric patients with atopic dermatitis.

NCT ID: NCT01960764 Withdrawn - Atopic Dermatitis Clinical Trials

Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival

Start date: June 2016
Phase: Phase 1
Study type: Interventional

Unlike healthy control skin, the skin of patients with atopic dermatitis (AD) is frequently colonized by Staphylococcus aureus (S. aureus), putting these patients at increased risk of S. aureus skin infections. In addition, research in the investigator's lab has shown that these patients have fewer protective antimicrobial Staphylococcal species such as Staphylococcal epidermidis (S. epidermidis) known to produce antimicrobial peptides that play a role in protecting the skin from invading pathogens. In this study, the investigator will attempt to decrease S. aureus colonization and increase colonization by protective Staph species. First the investigator will culture the bacteria on subjects' lesional AD skin. The investigator will selectively grow the subject's antimicrobial Staph colonies and place them into a base moisturizer. The moisturizer plus bacteria will be applied to both of the subject's arms. Prior to applying this, though, one arm will first be pre-treated with an antimicrobial regiment of Dial liquid antibacterial soap and alcohol. We will then compare the abundance of antimicrobial Staph species on each subject's arms 24 hours later to determine whether the pre-treatment regimen increased survival of the transplanted antimicrobial Staph species. The investigator expects that the arm pre-treated with the antimicrobial regimen will have more antimicrobial Staph species at this time point.

NCT ID: NCT01936194 Withdrawn - Atopic Dermatitis Clinical Trials

The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis

Start date: September 2013
Phase: N/A
Study type: Interventional

This clinical trial will study the effects of PUFA supplementation during pregnancy and lactation period on fatty acid composition in human milk and plasma of the mothers and the clinical outcome of atopic dermatitis in infants at increased risk.

NCT ID: NCT01695707 Withdrawn - Atopic Dermatitis Clinical Trials

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients

Start date: March 2013
Phase: N/A
Study type: Interventional

Many patients with eczema (atopic dermatitis) have an inherent defect in their skin barrier as demonstrated by high water loss. In laboratory conditions, studies have shown that pioglitazone restores the skin barrier function in skin from eczema patients. The purpose of this study is to determine if taking pioglitazone improves the skin barrier function in people with eczema.

NCT ID: NCT01691209 Withdrawn - Dermatitis, Atopic Clinical Trials

Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis

Phoenix
Start date: October 2013
Phase: N/A
Study type: Interventional

The study shall explore whether treatment of atopic dermatitis is equally effective with Phoenix medical device as compared to standard therapy (Hydrocortisone cream).

NCT ID: NCT01518348 Withdrawn - Contact Dermatitis Clinical Trials

Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents

PREAII
Start date: December 2012
Phase: Phase 3
Study type: Interventional

To evaluate the diagnostic performance (primary) and safety (secondary) of seven T.R.U.E. Test Panel 3.2 allergens: Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol in pediatric subjects 6-18 years of age with suspected contact dermatitis based on symptoms and clinical history.

NCT ID: NCT01385527 Withdrawn - Atopic Dermatitis Clinical Trials

Pediatric Atopic Dermatitis (AD) Internet Survey

Start date: June 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve atopic dermatitis treatment outcomes.

NCT ID: NCT01368315 Withdrawn - Atopic Dermatitis Clinical Trials

CT 327 in the "Atopy Patch Test" Model

CT327 AD01-09
Start date: n/a
Phase: Phase 1
Study type: Interventional

A Randomized, Double-Blind, Phase I, Single-Center Study on the Efficacy and Safety of CT 327 in the Atopy Patch Test model.

NCT ID: NCT01320046 Withdrawn - Clinical trials for Urinary Incontinence

Vulvar Contact Dermatitis Resulting From Urine Incontinence

Start date: March 2011
Phase: N/A
Study type: Observational

Vulvar contact dermatitis (VCD) is a common problem presenting as vulvar pruritus, burning or irritation. Its estimated prevalence is 20-30% in vulvar clinics, but the prevalence in the general population is unknown. Contact dermatitis is an inflammation of the skin resulting from an external agent that acts as an irritant or as an allergen. The skin reaction may be acute, subacute or chronic, resulting from prolonged exposure to weak irritating substances. The most common form of VCD is irritant contact dermatitis, and it usually presents as vulvar itch. The causes that contribute to VCD are increased sensitivity of the vulvar skin to irritants compared to other body parts, decrease in the skin barrier function due to exposure to sweat, urine and vaginal discharge and constant friction of the vulvar area. In menopausal women, lack of estrogen contributes to tissue atrophy and thinning, and may increase the effect of irritants on the vulvar skin. One of the most common irritating substances that cause VCD is urine. The phenomenon of urine-induced VCD is known as" diaper rash" in babies, and it was also described in bedridden patients using diapers constantly. Women with urine incontinence (UI), a problem that its prevalence in women increases with aging, may use constantly panty liners or pads to prevent urine leakage. The urine is being absorbed in the pad, and the vulvar skin is continually exposed to urine. This can cause VCD, similar to diaper rash. The prevalence of this phenomenon in the general population is unknown. The patients complain of itch, burning or irritation of the vulvar skin, and on exam erythema, edema and irritated skin are found. As most patients do not connect between UI to their vulvar disorder, and as most care-givers do not ask routinely about UI, the vulvar symptoms are mistakenly attributed to yeast infection or other factors. As the cause to the vulvar complaints is not recognized, patients do not receive proper treatment that requires primary management of UI. The aim of the study is to evaluate the prevalence of VCD in women with UI and to recognize risk factors for UI induced VCD.

NCT ID: NCT01230190 Withdrawn - Atopic Dermatitis Clinical Trials

Management of Eczema by Specific Probiotic Strains

BAMBOO
Start date: March 2011
Phase: Phase 3
Study type: Interventional

To investigate the therapeutic effect of a selected probiotic mixture on the severity of AD in infants aged 0-15 months. The probiotic mixture has been studied in laboratory setting and has proven IL-10 stimulating effects. Therefore it is thought to decrease AD severity in young children (beyond the conventional treatment).